Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes. From surgical innovations to artificial intelligence ...

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments. Increasingly, the choroid is being recognized ...

Modern Retina November and December 2025 | Modern Retina Digital Edition | Journal | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in ...

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants. As retinopathy of prematurity (ROP) ...

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology. The Health Canada approval was based on a “totality of evidence including ...

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation. As artificial intelligence (AI) continues to reshape the ...

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.Corza Medical has announced the commercial launch of the SensorTek ROP Kit, a single ...

An expert details practical imaging and counseling strategies for slowing vision loss in geographic atrophy through case-based management and patient engagement. Dr. Deepak Sambhara kicks off a ...

CoTx-10 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Coave Therapeutics has announced its lead gene ...

A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial. Nanoscope Therapeutics has released positive ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME. This ...